Meet Vium

Vium bridges the divide separating Silicon Valley innovation and preclinical drug research, where methodologies, systems, and tools have remained largely unchanged for decades.

Our team has developed the leading living informatics platform by incorporating core technology advancements in sensors, automation, and algorithms for processing big data.  Vium’s Digital Vivarium™ and Vium Cloud enable drug development researchers to make better decisions and conduct the highest quality studies in a fraction of the time compared with traditional methods.

We’re setting the standard for preclinical research by making drug development smarter and more efficient, and accelerating the process for bringing important breakthroughs to the people who need them.

Leadership

  • Wendel Barr, MBA

    Chief Executive Officer and Board Member

    Wendel has successfully led and driven long-term growth, operational excellence and expansion of major life sciences companies. Prior to joining Vium, Wendel was CEO and Board Member for SynteractHCR, leading the company through a transformative merger and growth phase to become a global leader in the mid-tier clinical research space. Previously, Wendel served as chief operating officer and executive vice president for Covance for the last three of his 10-year tenure with the company. In his first job at GE Healthcare, Wendel started as a field engineer then rose through the ranks into global leadership positions, including general manager. Wendel earned his B.S. in Electronics Engineering from DeVry Institute of Technology in Phoenix, Arizona and his MBA from National University in California.

  • Profile Joe Betts Lacroix

    Joe Betts-Lacroix

    Chief Technical Officer, Co-Founder, Board Member

    Joe was the primary technical founder of hardware/software startup OQO which entered the Guinness Book of World Records for building the smallest full-featured PC. His experience spans from biotech research to electronics design. Very experienced in invention, prosecution and monetization of intellectual property, he has over 80 Patents granted and pending in fields ranging from biophysics and safety systems to antennas, thermal systems, user interfaces and analog electronics. He has written numerous peer-reviewed publications in fields such as biophysics, genetics, electronics and robotics. Joe holds a Harvard A.B., MIT S.M. and Caltech research fellowship.

  • Alan Findlater, MBA

    Chief Commercial Officer

    Alan has spent over 30 years in pharmaceutical marketing and sales, including 15 years in business development for preclinical contract research organizations. He has a track record of delivering outstanding global sales results through strategic account focus, creative marketing strategy and sales leadership development. Alan started his career in the U.K. with global pharmaceutical companies, latterly Johnson & Johnson, before joining Covance to lead European business development. He then moved to the U.S. as Covance’s vice president of Sales and Client Services for North America, then assumed global positions in the Non-Clinical Safety Assessment and Analytical Services Divisions. Immediately prior to joining Vium, Alan was global executive sales director for Charles River Laboratories and chief commercial officer for WIL Research. Alan holds a B.S. in Chemistry with Honors from the University of Strathclyde and an M.B.A. from the University of Warwick.

  • Tom Hoster, MBA

    Chief Financial Officer

    Tom is an accomplished CFO who has spent 25 of his 35-plus year career in Silicon Valley, building and leading technology and medical device companies through rapid growth and organizational change. His extensive experience in finance and administration includes fundraising in both private and public markets, US and international operations, financial modeling and metrics, and investor relations, as well as development and non-profit leadership. Prior to Vium, Tom served as the CFO for medical device startups eNeura and EndoGastric Solutions. Tom serves on the National Annual Giving Committee at Princeton University. He holds a BSE degree in Electrical Engineering from Princeton University and an MBA from Stanford University.  

  • David Hutto, Ph.D., DVM, DACVP

    Chief Scientific Officer

    Dr. Hutto has extensive experience as a nonclinical pharmaceutical scientist and executive and has led key aspects of drug discovery and drug development leading in several cases to drug marketing approvals. Most recently David was at Charles River Laboratories as the Chief Scientific Officer of Safety Assessment, Veterinary Services and Animal Welfare and prior to that he was the Global Head of Drug Safety at Eisai, a biopharmaceutical company headquartered in Japan. David is a veterinarian with a PhD in immunology and specialty board certification in pathology and toxicology.

  • Larry Stevens

    VP Technology Operations

    Mr. Stevens has over 20 years of experience as an operations and development executive and has led multiple product launches and product ramps in emerging and multinational companies. Most recently Larry was at Robert Bosch Healthcare as the Vice President of Operations and Embedded Systems, where he was responsible for Global Operations and Hardware Development for Bosch’s medical device business unit. Prior to that, he was the Director of Manufacturing Operations at Curexo Technology Corporations and at several additional successful companies. Larry is certified in business management, portfolio, program and project management, and holds a Bachelor of Science in Technical Management and is a US Navy veteran.

  • Laura Schaevitz, Ph.D.

    VP of Scientific Technologies

    Laura Schaevitz has more than 15 years of experience with In vivo animal studies. As VP of Scientific Technologies at Vium, she oversees the development of animal models and draws upon her experiences as a molecular and behavioral neuroscientist to direct the application of Vium’s digital metrics to the animal models. In past experiences, Laura utilized a broad spectrum of mouse models including transgenic and nutrition-induced models of neurodevelopmental disorders such as autism, schizophrenia, Rett syndrome, and blindsight. Laura received her PhD in Neuroscience at Stanford University in 2006.

  • Daniel Ford, Ph.D.

    VP Software and Data Science

    Daniel Ford currently leads the Software and Data Science Division at Vium and is an expert in Data Science and Algorithms with over 20 years of experience in a wide range of applications. Dr. Ford earned his Phd from Stanford University in Mathematics applied to phylogenetics. Prior to Vium, he worked as Senior Statistician at Google, where he worked on topics ranging across search, global storage systems, social networks, down to memory allocators, and as VP of Software at Matterport, developing an end-to-end hardware-software system for creating, modifying, distributing, and navigating immersive 3D and virtual reality (VR) versions of real-world spaces. Dr. Ford’s other industry research and inventions range across applications including numerical algorithms, computational algebra, and simulations of electricity grids and markets.

Board Members

  • Matt Ocko

    Co-managing Partner, Data Collective

    Matt, co-Managing Partner and co-founder of Data Collective, has three decades of experience as a technology entrepreneur and VC. In addition to large IPO outcomes, many of Matt’s prior investments were acquired to become core capabilities of companies like Illumina, Cisco, Google, IBM, Amazon and Akamai. He is an inventor on over 40 granted or in-process patents. He has been active on a pro-bono basis in helping develop China’s venture capital and technology regulatory framework for two decades.

  • Dr. Annalisa Jenkins, MBBS, MRCP

    CEO, Dimension Therapeutics

    Dr. Jenkins has built and led teams advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. She is a member of the European Commission’s Scientific Panel for Health, a science-led expert group tasked with helping to achieve better health and wellbeing for all, and a committee member of the Science Board to the U.S. Food & Drug Administration, which advises FDA leadership on complex scientific and technical issues.

  • Jeff Kindler

    Former CEO, Pfizer

    Jeff is a partner at Lux Capital and senior advisor to Paragon Pharmaceuticals, a global investment firm that builds and manages innovative pharmaceutical companies. He serves on the boards of biotech companies, including PPD and Intrexon, and as a member of President Obama’s Management Advisory Board. Jeff formerly served as the Chairman and CEO of Pfizer, Chairman of PhRMA (Pharmaceutical Researchers and Manufacturers of America) and member of the board of the Federal Reserve Bank of New York.

Advisors

  • Timothy L. Robertson, Ph. D

    Co-Founder

    Tim co-founded Vium in 2013 and served as the company’s CEO until August 2017. As a physicist and serial entrepreneur, Tim’s vision for transforming the $10 billion preclinical drug development industry laid the foundation for Vium’s core technology, products, science, customer relationships, and team.

    He has more than 20 years of experience in all stages of technology start-up process, from invention and product development to commercialization and monetization. Prior to Vium, Tim was VP of Product Applications at Proteus Digital Health, responsible for management of alliances with global pharmaceutical companies, core technology coordination and software development. He is the holder of more than a dozen US patents and author of more than 40 scholarly publications in diverse fields. Tim has an A.B. in experimental physics and cosmology from Princeton University and Ph.D. in quantum physics from the University of California, Berkeley.

  • Nigel Brown, Ph.D.

    Former Chief of Strategy, Covance

    Dr. Nigel Brown, with over 25 years of experience in the pharmaceutical, biotech and contract research sectors, has executed more than 25 deals in the pharmaceutical R&D field, spanning acquisition, divestiture and strategic partnerships with combined transaction value in excess of $9 billion. He is extensively published in scientific and business literature, has advised governments on policy formulation related to pharmaceutical R&D, and has served on the boards of a number of biotech companies, including his role as Chairman of BioAxone Therapeutics.

  • Scott J. Dylla, Ph.D.

    Chief Scientific Officer & Co-Founder at Stemcentrx

    Scott Dylla is the co-founder and Chief Scientific Officer of Stemcentrx, where he oversees research and development activities. Scott trained as a postdoctoral scholar at Stanford University in the laboratory of Dr. Irving L. Weissman, where he was awarded American Cancer Society and Stanford Immunology fellowships, and was subsequently a Sr. Scientist at OncoMed Pharmaceuticals. In 2005, Scott was recognized by the British Council as one of eight outstanding young US-based researchers in the field of stem cell biology.

  • Clifford Roberts, DVM DACLAM

    Former President, American College of Lab Animal Medicine

    Clifford Roberts, DVM, is the former President of the American College of Lab Animal Medicine (ACLAM) and currently serves as associate vice chancellor of the Laboratory Animal Resource Center (LARC) within the University of California San Francisco Office of Research. A diplomate of the American College of Laboratory Animal Medicine, Roberts is the recipient of numerous honors and awards, including the US Army Surgeon General’s “A” Designation in Laboratory Animal Medicine. He received his BS and DVM degrees from Texas A&M University. Roberts previously served as deputy director at the Walter Reed Army Institute of Research, and as director/commander of the US Army Medical Research Unit in Kenya.

  • David Sinclair, Ph.D.

    Professor of Genetics, Harvard Medical School

    David Sinclair, Ph.D. is Co-Director of the Paul F. Glenn Center for the Biology of Aging, a Professor of Genetics at Harvard Medical School, Associate Member of the Broad Institute for Systems Biology and co-founder of Sirtris Pharmaceuticals. Dr. Sinclair has received several prestigious awards including a Special Fellowship from the Leukemia Society, a Ludwig Scholarship and an American Association for Aging Research Fellowship. He’s also won the Genzyme Outstanding Achievement in Biomedical Science Award for 2004.

Let’s advance human health together.

We’re helping scientists and businesses bring important new treatments to market faster than ever.

We're always looking for smart, purpose-driven team members specializing in preclinical sciences and software engineering to build on our solution. Want to use your experience to help save lives?

Join the Team